A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. UK Moclobemide Study Group.
The reversible, selective monoamine oxidase A inhibitor moclobemide (450 mg daily) was compared with imipramine (150 mg daily) and placebo in a multicentre, controlled clinical trial lasting 6 weeks. Two hundred and forty-nine patients participated, with a major depressive episode according to DSM-III criteria, and whose initial Hamilton Depression Scale rating (HDRS) was at least 17. Clinical improvement, as determined by HDRS, was similar in the three treatment groups: 53% of the evaluable patients in the moclobemide group responded (i.e. a 50% reduction in HDRS), compared with 50% on imipramine and 51% on placebo. Tolerability was least on imipramine, largely due to the high frequency of anticholinergic side effects; moclobemide showed no difference from placebo in this respect.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D011446:Prospective Studies
D000928:Antidepressive Agents; D001549:Benzamides; D007099:Imipramine; D020912:Moclobemide